Real-World Evidence and Change Control Plans Are Emerging as the Missing Infrastructure for Adaptive Digital Health
A new analysis argues that real-world evidence and predetermined change control plans could accelerate adoption of digital health technologies, especially those that evolve after launch. The idea is increasingly central to AI regulation: if software can change, the oversight model has to account for controlled change rather than freeze products in time.
One of the most important unresolved questions in health AI is how to regulate products that improve, drift, or adapt over time. The discussion around real-world evidence and predetermined change control plans gets at that problem directly. Instead of treating post-market change as an exception, this framework assumes change is normal and should be managed prospectively.
That matters because many of the most useful digital health and AI products do not fit a static approval model. Performance may vary by site, population, workflow, and software version. If regulators and manufacturers can agree in advance on what kinds of updates are expected, how they will be validated, and what evidence will be collected in deployment, innovation can move faster without abandoning safety controls.
For developers, this is also a business issue. Health systems are often wary of buying tools that may change unpredictably after implementation. Structured change-control frameworks could make procurement easier by clarifying what updates are allowed, what monitoring will occur, and how customers will be informed. In effect, regulatory design becomes part of commercial trust.
The larger shift is conceptual. Digital health oversight is moving away from a one-time gatekeeping mindset toward lifecycle governance. Real-world evidence is not just supplemental data anymore; it is becoming part of the operating logic for how software-based medicine proves it remains safe and useful in the wild.